113 results on '"Crippin J"'
Search Results
2. PERIOPERATIVE BLOOD TRANSFUSION AFFECTS OUTCOME AND HEPATITIS C VIRUS SPECIFIC IMMUNE RESPONSES FOLLOWING LIVER TRANSPLANTATION IN HEPATITIS C RECIPIENTS: BF114
3. A Consolidated Biovigilance System for Blood, Tissue and Organs:: One Size Does Not Fit All
4. Liver Allograft Injury Post Treatment of Hepatitis C (HCV) with Pegylated Interferon alfa (PEG IFN) and Ribavirin (RIBA): Factors Favoring an Immune Mediated Hepatitis (IMH)?: Abstract# 1371: Poster Board #-Session: P238-III
5. Regulation of Hepatitis C Virus Specific IFN-γ and IL-17 and Allograft Fibrosis by Programmed Death Receptor (PD-1) Following Liver Transplantation.: Abstract# 1363: Poster Board #-Session: P230-III
6. HCV Induced Changes in microRNA 449a and Its Role in Modulating the Expression of the Inflammatory Biomarker: Abstract# 1136: Poster Board #-Session: P3-III
7. Poster Board #-Session: P4-I DNA Binding Transcription Factors NF Kappa β (P65) and CEBPa Cooperate in Regulating the Expression of the Inflammatory Biomarker YKL40 in Human Hepatocytes.: Abstract# 536
8. Characterization of HCV-Specific CD4+Th17 Immunity in Recurrent Hepatitis C-Induced Liver Allograft Fibrosis
9. POST-TRANSPLANTATION (LT) SIGNIFICANT HCV-RELATED DISEASE SEVERITY: INCREASE IN RECENT YEARS
10. A PROSPECTIVE CONTROLLED TRIAL OF TACROLIMUS vs CYCLOSPORINE IN ORTHOTOPIC LIVER TRANSPLANT (OLT) RECIPIENTS WITH HEPATITIS C VIRUS: LACK OF EFFECT ON HCV RNA
11. Review article: interferon and hepatitis C-factors predicting therapeutic outcome
12. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial
13. 23 PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR HEPATITIS C RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANTATION (OLT): FINAL RESULTS FROM THE PROTECT STUDY
14. Elevation of serum riboflavin carrier protein in hepatocellular carcinoma
15. INTERIM ANALYSIS OF A SINGLE-CENTER, PROSPECTIVE, RANDOMIZED TRIAL COMPARING TACROLIMUS VERSUS CYCLOSPORINE IMMUNOSUPPRESSION USING 2 HOUR POST DOSE (C2) MONITORING IN DE NOVO LIVER TRANSPLANT RECIPIENTS
16. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation
17. Bone disease after liver transplantation
18. 121Marked increase in post-transplantation (LT) HCV-related fibrosis progression in recent years
19. TWO PTS UNDERGO LIVER ALLOTRANSPLANTATION (OLTX) FOLLOWING EXTRACORPOREAL HEPATIC SUPPORT WITH TRANSGENIC (hCD55/hCD59) PORCINE LIVERS: CLINICAL RESULTS AND LACK OF PIG TO HUMAN TRANSMISSION OF THE PORCINE ENDOGENOUS RETROVIRUS (PoERV).
20. OUTCOME 10-YEARS AFTER LIVER TRANSPLANTATION
21. INCIDENCE AND RECURRENCE OF AUTOIMMUNE HEPATITIS IN LIVER TRANSPLANT RECIPIENTS
22. ORTHOTOPIC LIVER TRANSPLANTATION (OLT) FOR HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION.
23. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin (HBIg) in reducing the incidence of acute rejection post-transplantation
24. A multicenter, randomized trial of daily, high dose interferon-alpha 2b for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotype
25. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease
26. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
27. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
28. Increased Intracranial Pressure and Hepatic Encephalopathy in Chronic Liver Disease.
29. Use of anti-hepatitis C virus seropositive organs in liver transplantation
30. Hepatocellular injury following the administration of propofol.
31. Intensive daily high dose interferon does not overcome antiviral reslstance in African Americans with chronic hepatitis C
32. The Control of Liquid Petroleum Gas and other highly flammable substances in wholesale and retail premises
33. Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study.
34. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. A Pilot Study.
35. Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients.
36. Modulation of immune responses following solid organ transplantation by microRNA.
37. Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
38. Incentives for organ donation: proposed standards for an internationally acceptable system.
39. Advanced donor age alone does not affect patient or graft survival after liver transplantation.
40. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
41. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis.
42. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
43. Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease.
44. Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
45. A model to predict severe HCV-related disease following liver transplantation.
46. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
47. Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitis.
48. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.
49. Celiac sprue: another autoimmune syndrome associated with hepatitis C.
50. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.